August 10, 2021
Cronos Group Inc. to Speak at the Canaccord Genuity 41st Annual Growth Conference
TORONTO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an…
Pharmaceuticals, Biotechnology and Life Sciences
TORONTO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an…
Central Nervous System Pipeline Progressing with Two Phase 2 Studies (TNX-1300 and TNX-1900) and One Phase 3 Study (TNX-102 SL)…
-Q2 2021 Total Net Revenues of $36.4 Million Reflect Strong Quarter over Quarter Growth -Q2 2021 GAAP Net Income of…
Monthly information regarding the total number of voting rights and total number of shares of the Company as of July…
TORONTO and CHICAGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) announced…
EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its…
– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444…
— NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior…
On track to report initial VOR33 clinical data in the first half of 2022Announced collaborations with Abound Bio and Janssen…
Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 MeetingImsidolimab GALLOP GPP Phase…